Dr. John Cush RheumNow
10 months 4 weeks ago
QD Clinic: Rapidly progressive RA ILD - or not?
Dr. Richard Conway, a rheumatologist in Dublin, Ireland, discusses whether this case shows rapidly progressing RA-ILD, or not, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/YC8XFiqZmd
Dr. John Cush RheumNow
10 months 4 weeks ago
Rheumatoid Arthritis ILD Complications
https://t.co/gAZCGTwHLB https://t.co/qcMmDuxXYx
Dr. John Cush RheumNow
10 months 4 weeks ago
Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA
A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD).
https://t.co/3AISriCUeC https://t.co/nN03e4ZBDU
Dr. John Cush RheumNow
10 months 4 weeks ago
🌐 ILD Treatment Guidelines – LIVE Webinar
📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST
An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies.
Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator
https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH
Aurelie Najm AurelieRheumo
10 months 4 weeks ago
Ellen Gravallese update on RA pathogenesis
Her take on RA interception studies
“While drug repurposing has not proven capable of preventing transition from Pre RA to RA, we need to better understand disease mechanisms to offer other interventions”
@RheumNow #APLAR25 @APLAR_org https://t.co/d39ihVvWyA
sheila RHEUMarampa
10 months 4 weeks ago
One of the most impt updates recommended to add a bDMARD if tx target is not achieved by the 1st csDMARD (no more prognostic stratification)
But, accdg to Dr. Smolen, adding a 2nd csDMARD should still be considered especially in resource-limited countries.
@RheumNow #APLAR25 https://t.co/ZQiviGcrYp
sheila RHEUMarampa
10 months 4 weeks ago
Dr. Josef Smolen discusses 2025 EULAR updates for RA.
He highlighted the importance of OP A - that tx should be a shared decision making between px and rheuma in order to ensure better care and disease control.
@RheumNow #aplar25 #APLAR25 https://t.co/KOJbiK87TS
Dr. John Cush RheumNow
10 months 4 weeks ago
Methotrexate significantly lowers Systolic BP
Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs. https://t.co/HDnDWahuul
Dr. John Cush RheumNow
10 months 4 weeks ago
SSc-ILD ABs & LESSONS:
30% of won't progress.
Triple negatives (ATA, ACA, ARA) wont progress.
Males & diffuse dz > predictive than Abs.
Great read on if Abs are biomarkers to predict Rx effect. https://t.co/YcZt4aAvL0 https://t.co/wOknKRfRHf
Dr. John Cush RheumNow
10 months 4 weeks ago
ACR Concerns on the Scientific Integrity at the CDC
On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to https://t.co/P2J7eZN07W
The unveiling of the updated 2025 recommendations for RA treatment, presented by Josef Smolen in the plenary session on the first day of the conference, sparked attention. Although not yet formally published, these updated recommendations represent a refined consensus that simplifies decision-making while reinforcing the importance of treat-to-target principles in RA.
Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one unifying truth: they are almost always serious, progressive, and life-altering. But for many patients, the burden of disease does not fall evenly. We are increasingly learning that where you live, who you are, and the resources available to you, can strongly influence how ILD develops and worsens. Understanding these disparities is
Dr. John Cush RheumNow
11 months ago
Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression didnt reduce odds of PAH (OR 0.74, p=0.495), early mycophenolate was protective(OR 0.12; p=0.048). Only HCQ use signif. improved survival (HR 0.04; p= 0.004). https://t.co/DbsJVZ16Zd
